Macular impairment in fabry disease: A morpho-functional assessment by swept-source OCT angiography and focal electroretinography by Minnella, A. M. (ORCID:0000-0001-5896-5313) et al.
Retina
Macular Impairment in Fabry Disease: A Morpho-
functional Assessment by Swept-Source OCT Angiography
and Focal Electroretinography
Angelo Maria Minnella,1,2 Lucilla Barbano,3 Elena Verrecchia,4 Francesco Martelli,5 Valeria
Pagliei,1 Gloria Gambini,1 Giorgio Placidi,1 Benedetto Falsini,1,2 Aldo Caporossi,1,2 and Raffaele
Manna4
1Institute of Ophthalmology, Universita` Cattolica del S. Cuore, Rome, Italy
2Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
3IRCCS- Fondazione Bietti, Rome, Italy
4Periodic Fever and Rare Diseases Research Centre, Universita` Cattolica del S. Cuore, Fondazione Policlinico Universitario A.
Gemelli IRCCS, Rome, Italy
5Department of Cardiovascular, Dysmetabolic and Aging-associated Diseases, National Institute of Health, Rome, Italy
Correspondence: Lucilla Barbano,
IRCCS- Fondazione Bietti, Via Liven-
za 3, Rome 00198, Italy;
lucillabarbano@gmail.com.
Submitted: October 25, 2018
Accepted: May 24, 2019
Citation: Minnella AM, Barbano L,
Verrecchia E, et al. Macular impair-
ment in Fabry disease: a morpho-
functional assessment by swept-
source OCT angiography and focal
electroretinography. Invest Ophthal-
mol Vis Sci. 2019;60:2667–2675.
https://doi.org/10.1167/iovs.18-26052
PURPOSE. Fabry disease (FD) is a multiorgan X-linked condition characterized by a deficiency of
the lysosomal enzyme alpha-galactosidase A, resulting in a progressive intralysosomal
deposit of globotriaosylceramide. The aim of this study was to evaluate the macular
ultrastructure of the vascular network using optical coherence tomography angiography
(OCTA) and to evaluate macular function using focal electroretinography (fERG) in Fabry
patients (FPs).
METHODS. A total of 20 FPs (38 eyes, mean age 57 6 2.12 SD, range of 27–80 years) and 17
healthy controls (27 eyes, mean age 45 years 6 20.50 SD, range of 24–65 years) were enrolled
in the study. Color fundus photography, swept-source optical coherence tomography (SS-
OCT), OCTA and fERG were performed in all subjects. The OCTA foveal avascular zone (FAZ),
vasculature structure, superficial and deep retinal plexus densities (images of 4.5 3 4.5 mm)
and fERG amplitudes were measured. Group differences were statistically assessed by
Student’s t-test and ANOVA.
RESULTS. In the FP group, the FAZ areas of the superficial and deep plexuses were enlarged (P
¼ 0.036, t ¼ 2.138; P < 0.001, t ¼ 3.889, respectively), the vessel density was increased in
the superficial plexus, and the fERG amplitude was reduced (P < 0.001, t ¼ 10.647)
compared with those in healthy controls. No significant correlations were found between the
structural and functional data.
CONCLUSIONS. OCTA vascular abnormalities and reduced fERG amplitudes indicate subclinical
signs of microangiopathy with early retinal dysfunction in FPs. This study highlights the
relevance of OCTA imaging analysis in the identification of abnormal macular vasculature as
an ocular hallmark of FD.
Keywords: Fabry disease, retina, OCT angiography, focal electroretinogram, innovative
biotechnology
Fabry disease (FD) (OMIM 301500) is a lysosomal storagedisorder resulting from a deficient or absent activity of the
lysosomal enzyme alpha-galactosidase A, which is encoded by
the GLA gene on chromosome X (Xq22). This enzyme is
involved in the degradation of glycosphingolipids, catalyzing
the galactose terminal hydrolysis of globotriaosylceramide
(GB3) by transforming it into lactosylceramide.1–3 In the
presence of GLA gene variants, the enzyme activity may be
reduced or absent, thus leading to the progressive deposition of
glycosphingolipids, including GB3, in various tissues, such as
the vascular endothelium, kidneys, smooth muscle cells, and
neuronal ganglions, resulting in subsequent cellular damage.
The clinical presentation and disease severity may vary;
although the onset of FD is often observed during childhood,
it worsens during adulthood. Acroparesthesia, skin angiokera-
tomas, abdominal pain, fever, and anhidrosis or hypohidrosis
are the most common symptoms in children. In adults, cardiac
involvement with arrhythmias and left ventricular hypertrophy,
cerebrovascular and renal dysfunction with proteinuria, and
progressive kidney failure predominate the symptoms. An early
diagnosis would lead to enzyme replacement therapy before
any irreversible damage, thus reducing the risk of disease
progression to organ failure.4,5 The time of therapy as well as
the individual response are important prognostic factors.
The ocular involvement in FD usually consists of corneal
abnormalities, which present as cornea verticillata, lens opacity,
and/or vascular abnormalities.6,7
Deposits of GB3 in the cornea take on a vortex pattern and
are located in the corneal epithelium, basal and Bowman’s
membranes, and the anterior stroma, whereas they have not
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been demonstrated in the endothelium.8,9 Anterior capsular
and radial posterior subcapsular cataracts, increased tortuosity,
or telangiectasia or small angiomas of conjunctival and retinal
vessels are frequently observed.10 Indeed, pathological depos-
its of GB3 in the vascular endothelium11,12 may induce
decreased vessel wall resistance to hydrostatic pressure,
resulting in vascular tortuosity13 and impaired tissue peripheral
perfusion.6,14
These vascular abnormalities have been studied to date with
color fundus photography and fluorescein angiography.10
The recent introduction of optical coherence tomography
angiography (OCTA) enables the assessment of retinal and
choroidal vascular flow features in several ocular vasculopa-
thies without the injection of dye.15 With the exception of a
few reports (Hufendiek K, et al. IOVS 2018;59:ARVO E-Abstract
5460; Baur J, et al. IOVS 2018;59:ARVO E-Abstract 4249), little
information regarding the use of OCTA in Fabry patients (FPs)
is available in the literature. To our knowledge, the relationship
between morphological retinal vascular changes in FD, which
are described using OCTA, and their functional implication, as
detected using focal electroretinography (fERG), has not yet
been underlined. The aim of this study was to evaluate the
superficial and deep capillary plexuses, the choriocapillaris
and the foveal avascular zone (FAZ) using OCTA and to
investigate macular function using fERG.
METHODS
The study was conducted at the Institute of Ophthalmology,
Universita` Cattolica del S. Cuore, Fondazione Policlinico
Universitario A. Gemelli IRCCS, in Rome (Italy) in accordance
with the principles of the Declaration of Helsinki.
The sample size of the study was preliminarily estimated by
considering the results of a pilot series of measurements (n ¼
10) obtained in FPs, as well as in controls. Assuming a standard
deviation of 20% for both the morphological and electrophys-
iological measurements, a total sample size of 36 subjects (20
FPs and 16 healthy controls) provided a power of 0.8, at a P
value of less than 0.05, to detect a between-group difference of
25%.
A total of 20 patients (38 eyes) with a diagnosis of FD were
enrolled between March 2017 and June 2017 (12 males and 8
females; mean age 57 6 2.12 SD; age range of 27–80 years).
All patients were selected from a larger cohort (n¼ 57) that
was followed by the Department of Periodic Fever and Rare
Disease Research Centre of the same university. Recruitment
was performed according to a collaboration between the two
departments and following an internal procedure of ocular
evaluation of FPs.
An age-matched group (mean age 45 6 20.50 SD, ranging
from 24 to 65 years) of 17 healthy subjects (10 males and 7
females), providing 27 eyes with no signs of any ocular disease,
served as controls.
The essential requirement to be included in the study was
an established diagnosis of FD demonstrated by performing an
enzymatic assay, which was confirmed by genetic testing. FPs,
aged 18 years or older, who were affected by different forms of
the disease (classic, mild, and late onset), which were defined
based on organ involvement and clinical features, were
included in this study. Patients were evaluated globally, and
disease severity was estimated using a severity score (Mainz
severity score index) based on general, cardiological, nephro-
logical, and neurologic involvement, which contributed to
emphasizing the heterogeneity of the sample.5 All data are
summarized in Table 1.
The comorbidity of diabetes, atherosclerotic vasculopathy,
glaucoma, or any other macular or retinal disorders was
regarded as exclusion criteria. Similarly, patients with optical
media opacity (lens opacity corresponding to a grading of >
N1, C2, P1 in accordance with the lens opacities classification
system 3)16 and/or those who had an inability to maintain or
difficulty maintaining visual fixation, which would have limited
visualization of the retinal structure and execution of the
functional examinations, were excluded from the study. Two
eyes in the FPs were excluded due to severe optic media
opacity (dense cataract C4) and retinal disorder (macular
pucker) in accordance with the exclusion criteria of the study;
among the controls, seven eyes were excluded because they
presented with myopia or hyperopia >2 diopters (D). The
remaining study eyes were emmetropic or slightly myopic (<1
TABLE 1. Genotype and Phenotype of the 20 FPs Included in the Study and the Corresponding Clinical Ocular Signs
Patient Genotype Phenotype Ocular Signs
1 c.548G>C Classical Cornea verticillata, cataract, conjunctival and retinal vessel tortuosity
2 c.758T>C Mild Normal
3 c.907A>T Mild Conjunctival, eyelid rim, and retinal vessel tortuosity
4 c.644A>G Late onset Conjunctival, eyelid rim, and retinal vessel tortuosity, cataract
5 c.747C>A Mild Normal
6 c.758T>C Classical Conjunctival and retinal vessel tortuosity
7 IVS5þ1G>T Classical Cataract, conjunctival and retinal vessel tortuosity
8 IVS5þ1G>T Classical Cataract, conjunctival vessel tortuosity
9 IVS3þ1G>A Classical Cornea verticillata, cataract, conjunctival and retinal vessel tortuosity
10 c.644A>G Late onset Conjunctival vessel tortuosity
11 c.548G>C Classical Cataract, conjunctival and retinal vessel tortuosity
12 c.548G>C Mild Cornea verticillata
13 c.644A>G Late onset Cornea verticillata, retinal vessel tortuosity
14 c.647 A>G Late onset Cataract, conjunctival and retinal vessel tortuosity
15 c.644A>G Late onset Cataract
16 c.730G>A Classical Cornea verticillata, conjunctival vessel tortuosity
17 c.644A>G Late onset Cornea ‘‘verticillata,’’ conjunctival and retinal vessel tortuosity, cataract
18 c.747C>A Mild Conjunctival vessel tortuosity
19 c.548G>C Mild Normal
20 c.647 A>G Classical Cornea ‘‘verticillata,’’ conjunctival and retinal vessel tortuosity, cataract
The phenotypes include classical (multiple, complete organ involvement), mild (incomplete organ involvement), and late onset (occurring in
adult age or involving a single organ or system).
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SPH D). Given such small refractive errors, axial length was not
predicted to influence FAZ or vessel density measurements.
All patients underwent a full ophthalmological examination,
including best corrected visual acuity (BCVA) and IOP
measurements, as well as anterior segment slit lamp biomi-
croscopy and fundus ophthalmoscopy after pupil dilation with
tropicamide 1% eye drops.
Color fundus images, structural OCT three-dimensional
(3D) scans and OCTA 4.5 3 4.5-mm images were obtained
using a DRI Triton Swept-Source OCTA device (Topcon, Tokyo,
Japan). The quality of the B-scans was evaluated using the
TopQ index provided by the device software. As far as OCTA,
the quality was assessed on the basis of the mean value of the
TopQ calculated as the average of the quality indexes of all the
B-scans an OCTA image is composed of. Only scans provided
with a TopQ >30 were retained for further analysis, and all the
images and scans outside this limit were discarded.
The level of segmentation for each capillary plexus was
automatically provided by the instrument: to detect the
superficial capillary plexus, the upper segmentation line was
situated at 2.6 lm under the inner limiting membrane, whereas
the lower segmentation line was located 15.6 lm under the
junction between the inner plexiform layer (IPL) and inner
nuclear layer (INL). To identify the deep capillary plexus,
segmentation lines were placed 15.6 lm under the junction
between the IPL and INL and 70.2 lm under the junction
between the IPL and INL. To detect the choriocapillaris,
segmentation lines were positioned at the level of Bruch’s
membrane and 10.4 lm beneath it.
All B-scans were reviewed by two expert graders (AMM, LB)
to exclude cases of failed segmentation. In cases of incorrect
automatic segmentation, segmentation boundaries were man-
ually adjusted. OCTA measurements of the FAZ area were
performed by two investigators (AMM, LB) who were blinded
to the clinical diagnosis, as well as to each other’s findings.
Spearman’s rank-order correlation analysis was carried out. The
agreement between the results of the investigators’ analyses
was satisfactory (correlation coefficient > 0.8). The FAZ area
was manually calculated on the en face scans of the superficial
and deep capillary plexuses.
The superficial and deep capillary plexus images were
analyzed after applying the device proprietary projection
artifact removal algorithm. OCTA scans (320 3 320 pixels,
24-bit RGB) of the superficial (layer 1) and deep capillary
plexuses (layer 2) and of the outer retinal (layer 3) and
choriocapillaris (layer 4) layers were checked for projection
artifacts, computing 2D correlation coefficients between layers
for each eye.17,18 Scans with correlation coefficients greater
than 0.25 (six FP eyes and one control eye) were discarded.
Projection-free OCTA images of the 16 FPs (30 eyes, 120
images) and of the 10 age-matched healthy controls (19 eyes,
76 images) were selected for further analysis. The images were
processed with a specifically developed algorithm, analogous
to that reported by Kim et al.,19 implemented in MATLAB
(MathWorks, Inc., Natick, MA, USA) to compute a vascular
density score for each image.
In detail, the following steps were performed:
1. The RGB images were converted to grayscale, eliminat-
ing the hue and saturation information while retaining
the luminance, following International Telecommunica-
tion Union Recommendation BT.601.7,20 Annex 2.
2. A modified version21 of Niblack’s algorithm22 was used
to remove uneven background luminance artifacts.
3. The image contrast was enhanced using histogram
equalization.
4. Image binarization was performed following the method
of Ridler and Calvard.23
5. Binary image morphological operations24 (spur, majority,
fill) were performed.
The density score was calculated as a ratio (expressed as a
percentage) of the number of pixels of the corresponding
vascular tissue to the total number of pixels in the image.25
Eight randomly chosen layer 1 angiographic images (four
FPs, four controls; two right eyes and two left eyes for FPs and
controls) were manually segmented by skilled operators (AMM,
LB) to obtain a ground truth segmentation for comparison with
the segmentation obtained using the algorithm.
A representative image of the eye of an FP that was analyzed
with this system is shown in Figure 1.
fERG was performed as described in previously published
works.26 We assessed a monocular recording with an Ag-AgCl
electrode taped on the skin over the lower eyelid after pupil
dilation with tropicamide 1% eye drops. A similar electrode
was placed over the eyelid of the contralateral patched eye and
was used as a reference. Stimuli consisted of flickering uniform
fields that were generated by an array of eight red light-emitting
diodes (LEDs) covering an 188 diameter with a mean luminance
FIGURE 1. (Left) Density scores for the superficial vascular plexus (layer 1), deep capillary plexus (layer 2), outer retina (layer 3) and the
choriocapillaris (layer 4) and subject type (Pt, patients; C, Controls) (** significant differences). (Right) OCTA images in a representative eye of a
patient with FD: (A) original image; (B) detected superficial capillary layer (layer 1); (C) superimposition of images (A) and (B), with the numerical
density score shown.
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of 80 cd/m2 and a temporal frequency of 41 Hz. The dominant
wavelength of the stimulus was 630 nm. The flickering
stimulus was sinusoidally produced by a custom-made digital
frequency generator and presented on the rear of a modified
Ganzfeld bowl (Primus; LACE Elettronica, Pisa, Italy) that was
illuminated at the same mean luminance as the stimulus.
For the purpose of this study, we used a stimulation
frequency of only 41 Hz. This frequency, under our experi-
mental conditions, was optimal for the amplitude of the first
harmonic component, as originally reported by Seiple et al.27
and subsequently confirmed by our group.28,29 In addition, it is
well established that a 41-Hz flicker reflects the activity of both
photoreceptors and bipolar cells.28 A diffusing filter was placed
in front of the LED array to make it appear as a circle of
uniform red light. A steady DC signal maintained the mean
luminance of the stimulus. A small square marker was placed in
the center of the Ganzfeld bowl to allow steady fixation on the
foveal region. The examined subjects were placed at a distance
of 30 cm from the stimulus.
fERG signals were amplified, filtered (bandpass filter
between 1 and 250 Hz), and averaged (12-bit resolution, 2-
kHz sampling rate, 1600 repetitions in eight blocks). Signals
exceeding the threshold voltage (25 mV) were rejected to
minimize noise coming from blinks or eye movements. After
the recording, a Fourier discrete analysis was performed to
isolate the fERG first harmonic (1F), and its peak-to-peak
amplitude was measured. Averaging and Fourier analyses also
were performed on signals that were sampled asynchronously
at 1.1 times the temporal frequency of the stimulus to estimate
the background noise at the fundamental component. Under
these conditions, the recorded fERG data were above the noise
level (noise amplitude <0.08 mV in all cases) and were
sufficiently reliable (the variation coefficient in amplitude
was 20%).
For each patient and control, only the results from one eye
(typically the right eye) were included in the statistical analysis;
this was performed for all fERG and morphometric analyses for
vascular density. Comparisons of the FAZ area and fERG
amplitudes between patients and healthy controls were
performed by independent two-tailed Student’s t-tests. A P
value less than 0.05 was considered statistically significant in
all comparisons.
An independent samples t-test was conducted to compare
the vascular density score in the images of both eyes of the FPs
and controls.
A 2-way ANOVA with a post hoc Tukey test was conducted
to compare the main effects of subject type (patient, control)
and retinal layers (1, 2, 3, 4 as described above) on the density
score. A P < 0.01 was chosen as the level of significance for
this correlation.
In comparing FPs and controls, the potential for age bias
was evaluated by testing the effect of age by linear regression
analysis on morphometric and electrophysiological measure-
ments. No significant effect of age was detected in the 40 to 60
age range; therefore, no correction for age was applied to the
data.
RESULTS
The mean BCVA among the 20 patients (38 eyes) who were
diagnosed with FD and included in our study was 83 letters
Early Treatment Diabetic Retinopathy Study (ETDRS) (corre-
sponding to 0.04 logMAR) in the right eye and 84 (0.02
logMAR) in the left eye. The mean BCVA in the group of the
healthy controls was 90 letters ETDRS in the right eye (0.10
logMAR) and 92 in the left eye (0.14 logMAR). For BCVA, no
significant difference was found between the FPs and controls.
Among the prototypical findings of FD, cornea verticillata
(Fig. 2A), increased tortuosity of the conjunctival vessels (Fig.
2B), increased tortuosity of vessels on the eyelid rim, anterior
and posterior cortical opacity, and increased tortuosity of the
retinal vessels (Fig. 2C) were observed in 7, 14, 3, 10, and 11
patients affected by the disease, respectively.
All patients in both groups had a normal IOP, a mean value
of 13.5 mm Hg in FP and a mean of 13 mm Hg in controls. No
alterations in macular thickness, morphology, and/or reflectiv-
ity were observed on OCT 3D scans in either FPs or controls.
In detail, a qualitative analysis of the OCTA scans showed a
rarefaction of the superficial and deep retinal capillary
plexuses, with the latter being more compromised, as a
reduction in the blood flow in the perifoveal area (see also Fig.
6) was also noticed in the eyes of FPs compared to those of
controls.
FIGURE 2. Ophthalmological features of FD: (A, top left) cornea verticillata; (B, top middle) increased tortuosity of conjunctival vessels with
angiomatosis and telangiectasia; (C, top right) increased tortuosity of retinal vessels. The table indicates the distribution of the listed
ophthalmological signs in study patients. OU, both eyes; RE, right eye.
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As a further confirmation of these findings, manual
measurement of the FAZ on the OCTA scans was carried out.
The mean values of the FAZ areas on the superficial and deep
capillary plexuses were 274.01 6 137.62 SD and 428.69 6
164.47 SD in FPs and 209.62 6 98.16 SD and 288.04 6 105.96
SD in controls. Further analysis of these data revealed a
statistically significant enlargement of the FAZ; mean values for
both the deep (P < 0.001, t¼3.889) and the superficial (P <
0.05, t¼ 2.13) vascular plexuses in the FP group compared to
those in the control group (Figs. 3A, 3B).
fERG amplitude values (lV) obtained in FPs and in controls
were 0.87 6 0.41 SD and 2.22 6 0.24 SD, respectively. A
significantly lower fERG mean amplitude was found in FPs than
in controls (P < 0.001, t ¼ 10.647) (Fig. 3C), whereas the
fERG phase did not show any significant differences between
the groups (t-test not significant) (Fig. 4).
Although a trend toward an association between FAZ
enlargement and reduction in fERG amplitude was noticed in
the eyes of the FP group, no significant correlations between
FAZ enlargement values and fERG amplitude or phase
measurements were observed in the eyes of FPs (Fig. 5).
A vascular density score was computed for the superficial
(layer 1) and deep capillary plexuses (layer 2), the outer retina
(layer 3) layers, and the choriocapillaris (layer 4). The mean
vascular density values in the FP group were 14.57 6 1.10,
9.37 6 1.02, 5.54 6 0.51, and 6.69 6 0.71 for layers 1, 2, 3,
and 4, respectively. The vessel density values were 13.33 6
0.59 (layer 1), 8.46 6 1.00 (layer 2), 5.27 6 0.38 (layer 3), and
6.40 6 0.66 (layer 4) among the controls. No significant
differences in the vascular density scores between the left
(mean 8.91 6 3.45 SD) and right (mean 8.90 6 3.54 SD) eyes
(P ¼ 0.93; t[55] ¼0.09) were found in the FP group.
The descriptive statistics of the computed density scores
are reported in Table 2.
There was a statistically significant effect of the group on
the vascular density score (P < 0.001; F[1.96] ¼ 17.29) as a
result of a significant mean difference between the FPs (mean
9.04 6 3.61 SD) and controls (mean¼ 8.36 6 3.20 SD) (Table
3).
The main effect for the retinal layer yielded an F ratio of
F[3.96] ¼ 542.51 (P < 0.001), indicating a significant effect of
the retinal layer, as reported in Table 2. The interaction
between groups (patients, controls) and retinal layer was not
significant (F[3.96] ¼ 2.19, P ¼ 0.094). Tukey’s pairwise
comparison test revealed a significant (P < 0.01) increase in
the density score between the patients and controls in layer 1
(mean FD density increase ¼1.24) but not in layers 2, 3, or 4
(Table 4).
Segmentation algorithm performance was evaluated by
comparing manually segmented images with those obtained
with the binarization algorithm. The estimated algorithm
sensibility and specificity were 0.68 (0.32 error margin) and
0.94 (0.17 error margin), respectively.
Assessment with the Spearman rank-order analysis showed
no correlation between our results and the systemic severity of
the disease quantified by calculating the Mainz severity score
index.
DISCUSSION
FD is characterized by the progressive accumulation of GB3 in
any cell of the body, which leads to metabolic alterations and
thus to cellular dysfunction. Several studies that have been
performed in murine models have demonstrated that lysosomal
deposits of GB3 may inhibit the receptors that are involved in
the activation of the endothelial nitric oxide synthase enzyme,
thus altering the vasoconstriction/vasodilation ratio of periph-
eral circulation with a consequent abnormal expression of
endothelial K(Ca)3 channels.12,13 These alterations are thought
to be responsible for the development of vascular abnormal-
ities, such as increased tortuosity, telangiectasis, and microan-
eurysms. These vascular features may involve several organs,
such as the kidney, heart, and brain, leading to the
development of renal failure, coronary dysfunction, and stroke,
and they are thus responsible for the reduced life expectancy
in FPs.30–32
Vascular alterations also may affect the eye and the retinal
vasculature and may be related to retinal ischemia and its
complications.33–35 In our study, OCTA was used to investigate
the vasculature features of FPs. A qualitative observation of a
rarefaction of the retinal capillary plexuses, especially the deep
capillary plexuses, suggests the presence of subclinical retinal
ischemia, as previously found in several other retinal vasculo-
pathies36 (Fig. 6). Similarly, a significant enlargement in the FAZ
implies a structural impairment of the macular area vasculature
in this rare disease. These findings, however, were inconsistent
with preserved visual acuity.
FIGURE 3. Boxplot representation of the FAZ measurements from the superficial (A) and deep (B) plexus and the fERG amplitude values (C) in eyes
from an FP and a control (C).
TABLE 2. Descriptive Statistics for Computed Vascular Density Scores





Layer 1 13.33 6 0.59 14.57 6 1.10
Layer 2 8.46 6 1.00 9.37 6 1.02
Layer 3 5.27 6 0.38 5.54 6 0.51
Layer 4 6.40 6 0.66 6.69 6 0.71
All layers 8.36 6 3.20 9.04 6 3.61
Layers: superficial (layer 1), deep capillary plexuses (layer 2), outer
retina (layer 3), and choriocapillaris (layer 4).
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FIGURE 4. Representative examples of fERG recordings obtained from a typical FP and a control subject. On top, fERG tracings (eight blocks of
responses) and their grand average (red trace) are shown. On the bottom, polar diagrams showing the response vector amplitude (in microvolts)
and phase angle (in degrees) of the response fundamental harmonic (isolated by Fourier analysis) are reported. Note that the cluster of response
vectors recorded from the FP eye show reduced amplitude (reduced vector length) compared with that from the control. Response phases (vector
orientations) are similar between the representative patient and control.
FIGURE 5. Scatterplot of fERG amplitude values as a function of the deep plexus FAZ: enlargement of the FAZ did not show a significant direct
correlation with a reduction in the fERG amplitude (Left) or phase (Right). The data from both eyes are included in the figure.
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Consequently, the fERG method was used to further
investigate the macular function to objectively assess the outer
and middle retinal functional statuses. The deep capillary
plexus is placed between the INL and the outer plexiform
layer, where the bipolar cells are located and connected with
photoreceptors. Evidence of a decreased fERG amplitude with
preserved phase values in FPs suggests a subclinical dysfunc-
tion of the outer retinal layers.
All of these findings suggest that compromised vascular
blood supply can harm photoreceptors and bipolar cells.
However, no significant correlations were found between FAZ
enlargement and fERG values, implying that, in addition to
tissue perfusion deficits, other factors might be responsible for
the observed abnormalities in outer retinal function.
For instance, the importance of the choriocapillaris layer in
providing blood supply to the retinal pigment epithelium
(RPE) and the photoreceptor layers should be considered, with
a possible compensatory function of the more external ocular
vasculature on the retina. Another possible reason for fERG
abnormalities may be the accumulation of GB3 at the level of
the RPE and photoreceptor cell membrane, similar to what
occurs in the vascular endothelium, which may alter synaptic
signaling between bipolar cells and photoreceptor cells. In
fact, it is already known that lysosomal storage disorders may
impair membrane trafficking.37,38
All of these hypotheses need to be verified by further
histological or ultrastructural studies of the eyes from patients
with this rare disorder.
fERG may show high test-retest variability39 but also can be
correlated with OCT parameters when a concomitant reduc-
tion in outer nuclear layer thickness occurs. This phenomenon
is not the case for FD.
Automated measurements of vascular density scores of both
the superficial and the deep capillary plexuses were obtained
from an artifact-free subset of OCTA scans. FPs showed an
increased vascular density in the superficial plexus in
comparison with controls; this finding may be suggestive of
vascular tortuosity, which represents a typical feature observed
in FD.
The observation of FAZ enlargement associated with
rarefaction of retinal capillary plexuses together with an
increased vascular density may appear contradictory. However,
because an increased vascular tortuosity may affect OCT signal
reflectance, this outcome, in turn, may yield an increase in the
density score (defined as the ratio between the area detected in
the vessel and the total image area), even in cases with an
enlarged FAZ area. In this view, an increase in the density score
could be observed in subjects in whom expanded FAZ area
suggests a general blood supply impairment.
An investigation of the vascular involvement in patients
who are affected by FD was provided by the OCTA findings
and represents a major strength of this study. Moreover, the
combined use of OCTA to conduct a vascular structural
analysis and fERG to assess retinal function provides an even
deeper and more complete assessment. In this study, fERG can
be regarded as a helpful tool in the identification of subclinical
phases of FD, as supported by the fact that even in patients
with a preclinical stage of FD, a reduction in fERG values was
observed. In fact, two female FPs, whose medical conditions
did not require any therapy, showed no signs other than a
reduction in fERG amplitude. In our results, the decreased
fERG amplitude is a statistically significant value that is worth
considering.
The relatively small sample size is a major limitation of this
study. A potential limitation to the study is the measurement of
the eye’s refraction and not the axial length; it is plausible that
cataracts could change the lenticular contribution of refractive
error to offset any axial length issues (i.e., a short eye with a
myopic shift from the lens may be close to plano). Further
clinical studies will validate OCTA and fERG as essential tools
for the routine ophthalmological evaluation of patients who
are affected by FD.
FIGURE 6. OCTA images of the superficial and deep capillary plexuses
in the eyes of an FP and control, showing vascular tortuosity in the
superficial plexus and a rarefaction-like ischemic area in the deep
plexus of the eyes of the FP compared to those of the control.
TABLE 3. Two-way ANOVA That Was Computed for the Vascular Density Scores
Source of Variation df SS MS F P
Subject type 1 11.28 11.28 17.29 6.98E-0.5
Retinal layer 3 1062.15 354.05 542.51 0
Interaction 3 4.28 1.43 2.19 0.09447
Model 7 1168.92 166.99 255.88 0
Error 96 62.65 0.65 – –
Corrected total 103 1231.57 – – –
Subject type is patient or control. Significant effects are bold-faced. Alpha level ¼ 0.01. df, degrees of freedom; MS, mean square; SS, sum of
squares.
Macular Involvement in Fabry Disease IOVS j June 2019 j Vol. 60 j No. 7 j 2673
Downloaded from iovs.arvojournals.org on 07/11/2019
Acknowledgments
Supported by the Ministry of Health and Fondazione Roma and
Fondi di Ateneo linea D1, D3, Universita` Cattolica del S. Cuore
(AMM, BF).
Disclosure: A.M. Minnella, None; L. Barbano, None; E.
Verrecchia, None; F. Martelli, None; V. Pagliei, None; G.
Gambini, None; G. Placidi, None; B. Falsini, None; A.
Caporossi, None; R. Manna, None
References
1. El-Abassi R, Singhal D, England JD. Fabry’s disease. J Neurol
Sci. 2014;344:5–19.
2. Garman SC, Garboczi DN. The molecular defect leading to
Fabry disease: structure of human alpha-galactosidase. J Mol
Biol. 2004;337:319–335.
3. Dobrovolny´ R, Dvora´kova´ L, Ledvinova´ J, et al. Recurrence of
Fabry disease as a result of paternal germline mosaicism for
alpha-galactosidase a gene mutation. Am J Med Genet A.
2005;134A:84–87.
4. Masson C, Cisse´ I, Simon V, Insalaco P, Audran M. Fabry
disease: a review. Joint Bone Spine. 2004;71:381–383.
5. Whybra C, Kampmann C, Krummenauer F, et al. The Mainz
Severity Score Index: a new instrument for quantifying the
Anderson-Fabry disease phenotype, and the response of
patients to enzyme replacement therapy. Clin Genet. 2004;
65:299–307.
6. Sivley MD. Fabry disease: a review of ophthalmic and systemic
manifestations. Optom Vis Sci. 2013;90:e63–e78.
7. Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular
manifestations of Fabry’s disease: data from the Fabry
Outcome Survey. Br J Ophthalmol. 2007;91:210–214.
8. Mastropasqua L, Nubile M, Lanzini M, Carpineto P, Toto L,
Ciancaglini M. Corneal and conjunctival manifestations in
Fabry disease: in vivo confocal microscopy study. Am J
Ophthalmol. 2006;141:709–718.
9. Degirmenci C, Yilmaz SG, Onay H, et al. A novel mutation and
in vivo confocal microscopic findings in Fabry disease. Saudi
J Ophthalmol. 2017;31:45–47.
10. Dantas MA, Fonseca RA, Kaga T, Yannuzzi LA, Spaide RF.
Retinal and choroidal vascular changes in heterozygous Fabry
disease. Retina. 2001;21:87–89.
11. Satoh K. Globotriaosylceramide induces endothelial dysfunc-
tion in Fabry disease. Arterioscler Thromb Vasc Biol. 2014;
34:2–4.
12. Park S, Kim JA, Joo KY, et al. Globotriaosylceramide leads to
K(Ca)3.1 channel dysfunction: a new insight into endothelial
dysfunction in Fabry disease. Cardiovasc Res. 2011;89:290–
299.
13. San Roma´n I, Rodr´ıguez M-E, Caporossi O, et al. Computer
assisted retinal vessel tortuosity evaluation in novel mutation
Fabry disease: towards new prognostic markers. Retina.
2017;37:592–603.
14. Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Pinto A,
Licata G. Anderson-Fabry disease: a multiorgan disease. Curr
Pharm Des. 2013;19:5974–5996.
15. Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G.
Optical coherence tomography angiography. Prog Retin Eye
Res. 2018;64:1–55.
16. Chylack LT Jr, Wolfe JK, Singer DM, et al.; The Longitudinal
Study of Cataract Study Group. The Lens Opacities Classifi-
cation System III. Arch Ophthalmol. 1993;111:831–836.
17. Jonathan E, Enfield J, Leahy MJ. Correlation mapping method
for generating microcirculation morphology from optical
coherence tomography (OCT) intensity images. J Biopho-
tonics. 2010;4:583–587.
18. Baran U, Choi WJ, Li Y, Wang RK. Tail artifact removal in OCT
angiography images of rodent cortex. J Biophotonics. 2016;
10:1421–1429.
19. Kim T-H, Son T, Lu Y, Alam M, Yao X. Comparative optical
coherence tomography angiography of wild-type and rd10
mouse retinas. Trans Vis Sci Tech. 2018;7(6):42.
20. International Telecommunication Union. ITU recommenda-
tion BT.601–7 03 2011. Geneva, Switzerland: International
Telecommunication Union; 2011.
21. Sauvola J, Pietika¨inen M. Adaptive document image binariza-
tion. Pattern Recognit. 2000;33:225–236.
22. Niblack W. An Introduction to Digital Image Processing.
Englewood Cliffs: Prentice Hall; 1986.
23. Ridler T, Calvard S. Picture thresholding using an iterative
selection method. IEEE Trans Syst Man Cybern Syst. 1978;8:
630–632.
24. Lam L, Lee S-W, Suen CY. Thinning methodologies-a compre-
hensive survey. IEEE Trans Pattern Anal Mach Intell. 1992;
14:869–885.
25. Jia Y, Bailey ST, Hwang TS, et al. Quantitative optical
coherence tomography angiography of vascular abnormalities
in the living human eye. Proc Natl Acad Sci U S A. 2015;112:
E2395–E2402.
26. Abed E, Placidi G, Calandriello L, et al. Correlation of macular
focal electroretinogram with ellipsoid zone extension in
Stargardt disease. J Ophthalmol. 2017;2017:3643495.
27. Seiple WH, Siegel IM, Carr RE, Mayron C. Evaluating macular
function using the focal ERG. Invest Ophthalmol Vis Sci.
1986;27:1123–1130.
28. Falsini B, Ziccardi L, Stifano G, et al. Temporal response
properties of the macular cone system: effect of normal aging
and age-related maculopathy. Invest Ophthalmol Vis Sci.
2007;48:4811–4817.
29. Falsini B, Iarossi G, Fadda A, et al. The fundamental and
second harmonic of the photopic flicker electroretinogram:
temporal frequency-dependent abnormalities in retinitis
pigmentosa. Clin Neurophysiol. 1999;110:1554–1562.
30. Anastasakis A, Papatheodorou E, Steriotis AK. Fabry disease
and cardiovascular involvement. Curr Pharm Des. 2013;19:
5997–6008.
31. Gubler M-C. Le´sions re´nales dans la maladie de Fabry [in
French]. La Revue de Me´decine Interne. 2010;31:S220–S225.
TABLE 4. Tukey’s Honestly Significant Difference Test Results of the Mean Vascular Density Score Differences (Patient Score  Control Score)
Retinal Layer P  C Score SEM q Value Prob LCL UCL
Layer 1 1.24 0.33 5.38 0.01 0.05 2.42
Layer 2 0.92 0.33 3.98 0.10 0.27 2.10
Layer 3 0.27 0.33 1.16 0.99 0.92 1.45
Layer 4 0.28 0.33 1.24 0.99 0.90 1.47
Significant effects are in bold; Alpha level¼ 0.01. PC score, patient vascular density score control vascular density score; Prob, probability;
LCL, lower confidence limit; UCL, upper confidence limit.
Macular Involvement in Fabry Disease IOVS j June 2019 j Vol. 60 j No. 7 j 2674
Downloaded from iovs.arvojournals.org on 07/11/2019
32. Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral
vasculopathy of Fabry disease. J Neurol Sci. 2007;257:258–
263.
33. Sher NA, Reiff W, Letson RD, Desnick RJ. Central retinal artery
occlusion complicating Fabry’s disease. Arch Ophthalmol.
1978;96:815–817.
34. Abe H, Sakai T, Sawaguchi S, et al. Ischemic optic neuropathy
in a female carrier with Fabry’s disease. Ophthalmologica.
1992;205:83–88.
35. Pitz S, Grube-Einwald K, Renieri G, Reinke J. Subclinical optic
neuropathy in Fabry disease. Ophthalmic Genet. 2009;30:
165–171.
36. De Carlo TE, Romano A, Waheed NK, Duker JS. A review of
optical coherence tomography angiography (OCTA). Int J
Retina Vitreous. 2015;1:5.
37. Brogden G, Shammas H, Maalouf K, et al. Case study on the
pathophysiology of Fabry disease: abnormalities of cellular
membranes can be reversed by substrate reduction. Biosci
Rep. 2017;37:BSR20160402.
38. Kuech E-M, Brogden G, Naim HY. Alterations in membrane
trafficking and pathophysiological implications in lysosomal
storage disorders. Biochimie. 2016;130:152–162.
39. Galli-Resta L, Piccardi M, Ziccardi L, et al. Early detection of
central visual function decline in cone-rod dystrophy by the
use of macular focal cone electroretinogram. Invest Oph-
thalmol Vis Sci. 2013;54:6560–6569.
Macular Involvement in Fabry Disease IOVS j June 2019 j Vol. 60 j No. 7 j 2675
Downloaded from iovs.arvojournals.org on 07/11/2019
